Next Article in Journal
A Novel Prediction Tool for Endoscopic Intervention in Patients with Acute Upper Gastro-Intestinal Bleeding
Next Article in Special Issue
Treatment with Cenobamate in Adult Patients with Lennox–Gastaut Syndrome: A Case Series
Previous Article in Journal
The Present and Future of Clinical Management in Metastatic Breast Cancer
Previous Article in Special Issue
Replacement of Valproic Acid with New Anti-Seizure Medications in Idiopathic Generalized Epilepsy
 
 
Article
Peer-Review Record

Early Epilepsy Surgery in Benign Cerebral Tumors: Avoid Your ‘Low-Grade’ Becoming a ‘Long-Term’ Epilepsy-Associated Tumor

J. Clin. Med. 2022, 11(19), 5892; https://doi.org/10.3390/jcm11195892
by Catrin Mann 1,2,*, Nadine Conradi 1,2, Elisabeth Neuhaus 1,2,3, Jürgen Konczalla 2,4, Thomas M. Freiman 2,4,5, Andrea Spyrantis 2,4, Katharina Weber 6,7,8,9, Patrick Harter 6,7,8,9, Felix Rosenow 1,2, Adam Strzelczyk 1,2 and Susanne Schubert-Bast 1,2,10
Reviewer 1:
Reviewer 2: Anonymous
J. Clin. Med. 2022, 11(19), 5892; https://doi.org/10.3390/jcm11195892
Submission received: 12 September 2022 / Revised: 27 September 2022 / Accepted: 3 October 2022 / Published: 5 October 2022
(This article belongs to the Special Issue Current Challenges and Advances in the Treatment of Epilepsy)

Round 1

Reviewer 1 Report

- only few typos, spell check required / e.g. inconsistent use of capital letters in specific terms (as Low grade epilepsy associated tumors)

- last sentence of abstract: not the lesions themself are non-eloquent but the cortex in which the lesions are located. Please change.

- Please consider adding a patient characteristics table within the main text.

- Please add the number of patients that had been operated on without proof of pharmacoresistancy

- it would be interesting to add the number of patients that had been evaluated for epilepsy surgery at your center within the time period but did not proceed to surgery

- p2 l59: Please change the wording "worse seizure free outcome"

- 4.2 cognitive decline.... line 346: how is "relevant" cognitive deficits defined?

- Limitations: Please discuss the limitations by a heterogeneous cohort (age, type and location of tumor) in more detail. Within introduction you state (line 53) "due to patient diversity and small sample sizes, factors associated with seizure control remain incompletely understood." This issue is not completely solved by your study and should therefore be mentioned in limitations.

 

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

I thought the contents of the paper justified your case for earlier surgery to remove epileptogenic tissue in relation to ASM treatment-refractory epileptic seizures in persons with low grade neuroepithelial tumours. However, I wondered if your data would permit determination of when the post-surgery improvement in cognition occurred. If early, the benefit might arise from tumor tissue or seizure cessation, but if later, only after ASM dosage reduction or cessation, the interference would probably be medication-related, and a further reason for earlier surgery.

However, with earlier operation, you would have probably no longer have the ASM treatment-failure as an indication for operating. Do you have data on the proportion of these neuroepithelial tumours that produce seizures that are controlled by ASM therapy? Your earlier surgery idea might come to involve such persons. 

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop